Evidence map›Paper›PMID 36911680›Full record

ArticleFrontiers in immunology2023

Orally administered

Yimei Wang, Tomohiro Takano, Yingyu Zhou, Rong Wang, Takayuki Toshimitsu, Toshihiro Sashihara, Masaru Tanokura, Takuya Miyakawa, Haruyo Nakajima-Adachi, Satoshi Hachimura

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. An artificial mucus-integratedGut microbes reports · 2026
    Article
  3. Food science & nutrition · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Nutrients · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yimei WangResearch Center for Food Safety, The University of Tokyo, Tokyo, Japan.
Tomohiro TakanoResearch Center for Food Safety, The University of Tokyo, Tokyo, Japan.
Yingyu ZhouDepartment of Applied Biological Chemistry, The University of Tokyo, Tokyo, Japan.
Rong WangDepartment of Applied Biological Chemistry, The University of Tokyo, Tokyo, Japan.
Takayuki ToshimitsuCo-Creation Center, Meiji Holdings Co., Ltd, Hachiouji, Japan.
Toshihiro SashiharaCo-Creation Center, Meiji Holdings Co., Ltd, Hachiouji, Japan.
Masaru TanokuraResearch Center for Food Safety, The University of Tokyo, Tokyo, Japan.
Takuya MiyakawaDepartment of Applied Biological Chemistry, The University of Tokyo, Tokyo, Japan.
Haruyo Nakajima-AdachiResearch Center for Food Safety, The University of Tokyo, Tokyo, Japan.
Satoshi HachimuraResearch Center for Food Safety, The University of Tokyo, Tokyo, Japan.
The University of Tokyo · JPOji Holdings (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Chronic inflammation caused by dietary obesity has been considered to induce lifestyle-related diseases and functional ingredients with anti-inflammatory effects are attracting attention. Although multiple studies on obesity had proved the anti-inflammatory effects of ingestion of lactic acid bacteria (LAB) and other functional ingredients on adipose tissue, the precise effects on the intestine, especially on the individual intestinal segments have not been made clear. In this study, we elucidated the mechanisms of Methods: We orally administered heat-treated LAB to HFD-fed mice model, and investigated the inflammatory changes in adipose tissue and intestinal immune cells. We also analyzed gut microbiota, and evaluated the inflammation and permeability of the duodenum, jejunum, ileum and colon; four intestinal segments differing in gut bacteria composition and immune response. Results: After 3-week LAB administration, the gene expression levels of proinflammatory cytokines were downregulated in adipose tissue, colon, and Peyer's patches (PP)-derived F4/80 Discussion: Our results suggest that the oral administration of the LAB strain regulated the gut microbiota, suppressed intestinal inflammation, and improved the gut barrier, which could inhibit the products of obesity-induced gut dysbiosis from translocating into the bloodstream and the adipose tissue, through which the LAB finally alleviated the inflammation caused by dietary obesity. Barrier improvement was observed, especially in the ileum, suggesting collaborative modulation of the intestinal immune responses by ingested LAB and microbiota.

Indexed as

Gastrointestinal MicrobiomeLactobacillalesAnimalsAnti-Inflammatory AgentsIleumInflammationMiceObesityAnti-Inflammatory Agentsgut microbiotaintestinal permeabilitylactic acid bacteriamacrophagesobesityproinflammatory cytokines

Identifiers

PMID36911680
PMCPMC9995389
OpenAlexW4321601537

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.